- ISIN
- US00847G7051
- CUSIP
- 00847G705
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 4, 2000
Highlights
- Market Cap
- $123.28M
- Enterprise Value
- $98.11M
- EPS (TTM)
- $0.75
- PE Ratio
- 4.27
- Total Revenue (TTM)
- $123.87M
- Gross Profit (TTM)
- $38.34M
- EBITDA (TTM)
- $96.61M
- Year Range
- $2.71 - $7.34
- Target Price
- $7.33
- ROA (TTM)
- 13.61%
- ROE (TTM)
- -34.96%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
AGEN Performance Chart
Agenus Inc. (AGEN) is up 2.6% since the beginning of the year. At $3 per share, AGEN is trading 56.1% below its 52-week high of $7. Investors who bought $1,000 worth of AGEN shares 5 years ago would now be looking at an investment worth $41.
Loading charts...
Returns By Period
Agenus Inc. (AGEN) has returned 2.55% so far this year and -35.60% over the past 12 months. Over the last ten years, AGEN has returned -28.00% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.
Agenus Inc.
- 1D
- -4.73%
- 1M
- -19.90%
- YTD
- 2.55%
- 6M
- -22.78%
- 1Y
- -35.60%
- 3Y*
- -53.49%
- 5Y*
- -47.28%
- 10Y*
- -28.00%
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
AGEN Monthly Returns History
Based on dividend-adjusted daily data since Feb 8, 2000, AGEN's average daily return is +0.03%, while the average monthly return is +0.10%. At this rate, an investment would double in approximately 57.8 years.
Historically, 42% of months were positive and 58% were negative. The best month was Jun 2009 with a return of +186.3%, while the worst month was Jul 2024 at -63.9%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.
On a daily basis, AGEN closed higher 45% of trading days. The best single day was Jun 3, 2009 with a return of +73.2%, while the worst single day was Jul 18, 2024 at -58.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.55% | 17.25% | 0.30% | 17.07% | -10.49% | -8.00% | 2.55% | ||||||
| 2025 | 38.69% | -25.00% | -47.19% | 92.03% | 18.69% | 33.24% | 20.79% | -24.28% | -7.89% | 3.12% | 14.86% | -31.14% | 14.60% |
| 2024 | -19.41% | 0.42% | -13.43% | 4.48% | 29.46% | 6.76% | -63.94% | -14.74% | 6.41% | -23.36% | -18.57% | -19.88% | -83.45% |
| 2023 | 8.75% | -21.07% | -26.21% | 1.23% | 3.31% | 2.56% | -5.00% | -9.21% | -18.12% | -29.20% | -2.86% | 6.54% | -64.85% |
| 2022 | -14.29% | -2.17% | -8.89% | -24.80% | -9.73% | 16.17% | 32.99% | 4.65% | -24.07% | 22.44% | 7.57% | -11.11% | -25.47% |
| 2021 | 15.72% | 8.70% | -32.00% | 13.60% | 37.86% | 28.87% | -5.65% | 19.11% | -14.91% | -26.86% | -17.97% | 2.22% | 1.26% |
Benchmark Metrics
Agenus Inc. has an annualized alpha of -3.03%, beta of 1.19, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since February 09, 2000.
- This stock participated in 181.39% of S&P 500 Index downside but only 54.35% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -3.03%
- Beta
- 1.19
- R²
- 0.07
- Upside Capture
- 54.35%
- Downside Capture
- 181.39%
Return for Risk
Risk / Return Rank
AGEN ranks 25 for risk / return — below 25% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Agenus Inc. (AGEN) and compare them to S&P 500 Index.
| AGEN | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.40 | 2.24 | -2.64 |
Sortino ratioReturn per unit of downside risk | -0.08 | 3.07 | -3.16 |
Omega ratioGain probability vs. loss probability | 0.99 | 1.41 | -0.42 |
Calmar ratioReturn relative to maximum drawdown | -0.59 | 2.93 | -3.52 |
Martin ratioReturn relative to average drawdown | -0.84 | 13.52 | -14.36 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Agenus Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Agenus Inc. was 99.98%, occurring on Mar 31, 2025. The portfolio has not yet recovered.
The current Agenus Inc. drawdown is 99.95%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -99.98%Mar 2025 | 25y 27d | — | 26y 3moMar 2000 - now |
2000 bear market2000 | -23.90%Feb 2000 | 5d | 16d | 21dFeb 2000 - Mar 2000 |
2000 pullback2000 | -6.50%Feb 2000 | 0s | 4d | 4dFeb 2000 - Feb 2000 |
2000 pullback2000 | -4.86%Feb 2000 | 0s | 1d | 1dFeb 2000 - Feb 2000 |
Drawdown Indicators
| AGEN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.98% | -56.78% | -43.20% |
Max Drawdown (1Y)Largest decline over 1 year | -60.76% | -9.10% | -51.66% |
Max Drawdown (3Y)Largest decline over 3 years | -96.31% | -18.90% | -77.41% |
Max Drawdown (5Y)Largest decline over 5 years | -98.84% | -25.43% | -73.41% |
Max Drawdown (10Y)Largest decline over 10 years | -98.96% | -33.92% | -65.04% |
Current DrawdownCurrent decline from peak | -99.95% | -0.74% | -99.21% |
Average DrawdownAverage peak-to-trough decline | -93.66% | -10.72% | -82.94% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 42.62% | 1.97% | +40.65% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Agenus Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Agenus Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for AGEN, comparing it with other companies in the Biotechnology industry. Currently, AGEN has a P/E ratio of 4.3. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AGEN relative to other companies in the Biotechnology industry. Currently, AGEN has a P/S ratio of 0.9. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with AGEN
Add Agenus Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with AGEN